Our Camu Camu is gently dried at low temperatures to protect its broad range of nutrients and to preserve its deliciously tangy and tart flavor
Specifically, we requested comments on our proposal to revise 414.1380(b)(3) to read that, beginning with the CY 2025 performance period/2027 MIPS payment year, MIPS eligible clinicians (except for non-patient facing MIPS eligible clinicians, small practices, and practices located in rural areas and geographic HPSAs) receive 20 points for each improvement activity, while non-patient facing MIPS eligible clinicians, small practices, and practices located in rural areas and geographic HPSAs receive 40 points for each improvement activity
Moreover, combining these approaches with CRISPR/Cas9 genome editing offers transformative potential for personalized cell replacement therapies by enabling the precise genetic correction of hiPSCs, paving the way for individualized regenerative medicine strategies (189)
As described earlier in this final rule, after consideration of comments received, we revised 428.202(d) to add a paragraph (3), which provides that to the extent that a new NDC-9 of a Part D rebatable drug is reported under section 1927 of the Act and AMP has not been reported for such NDC-9 under section 1927(b)(3)(A)(i)(I) or (ii) of the Act during the period described 428.202(c)(1) or (2), as applicable, CMS will identify the payment amount benchmark period and calculate the benchmark period manufacturer price for such NDC-9 using other information reported by a manufacturer under section 1927(b)(3) of the Act for the Part D rebatable drug, as available, such as the base date AMP if such base date AMP is reported for a calendar quarter that overlaps with the period described at 428.202(c)(1) or (2), as applicable
